Penetration of clarithromycin into middle ear fluid of children with acute otitis media

Pediatric Infectious Disease Journal

Volumn 16, Issue 1, 1997, Pages 39-43

  Gan, Vanthaya N ^a   McCarty, James M ^b   Chu, Sou Yie ^c   Carr, Robert ^c  

^a CHILDREN S MEDICAL CENTER   (United States)

^b McCarty/Hernon Research Associates   (United States)

^c ABBOTT LABORATORIES   (United States)

Author keywords

Acute otitis media; clarithromycin; pharmacokinetics

Indexed keywords

14 HYDROXYCLARITHROMYCIN; ANTIBIOTIC AGENT; CLARITHROMYCIN; DRUG METABOLITE; MACROLIDE;

ACUTE DISEASE; ANTIBIOTIC THERAPY; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG PENETRATION; FEMALE; HUMAN; MALE; MIDDLE EAR; MINIMUM INHIBITORY CONCENTRATION; MYRINGOTOMY; ORAL DRUG ADMINISTRATION; OTITIS MEDIA; PRIORITY JOURNAL;

ACUTE DISEASE; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; CLARITHROMYCIN; EAR, MIDDLE; FEMALE; HUMANS; INFANT; MALE; OTITIS MEDIA WITH EFFUSION;

EID: 0031046484     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199701000-00009     Document Type: Article

References (18)

1. Neu HC. The development of macrolides: clarithromycin in perspective. J Antimicrob Chemother 1991;27(Suppl A):1-9.
2. Chin NX, Neu NM, Labthavikul P, Saha G, Neu HC. Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacteria. Antimicrob Agents Chemother 1987;31:463-6.
3. Kirst HA, Sides GD. New directions for macrolide antibiotics: structural modifications and in vitro activity. Antimicrob Agents Chemother 1989;33:1419-22.
4. Hardy DJ, Swanson RN, Rode RA, Marsh K, Shipkowitz NL, Clement JJ. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. Antimicrob Agents Chemother 1990;34:1407-13.
5. Chu SY, Sennello LT, Bunnell ST, Varga LL, Wilson DS, Sonders RC. Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses. Antimicrob Agents Chemother 1992;36:2447-53.
6. Chu SY, Wilson DS, Guay DR, Craft JC. Clarithromycin pharmacokinetics in healthy young and elderly volunteers. J Clin Pharmacol 1992;32:1045-9.
7. Chu SY, Wilson DS, Deaton RL, Mackenthun AV, Eason CN, Cavanaugh JH. Single and multiple dose pharmacokinetics of clarithromycin, a new macrolide antimicrobial. J Clin Pharmacol 1993;33:719-26.
8. Davey PG. The pharmacokinetics of clarithromycin and its 14-OH metabolite. J Hosp Infect 1991;19(Suppl. A):29-37.
9. McCarty JM, Phillips A, Wiisanen R. Comparative safety and efficacy of clarithromycin and amoxicillin/clavulanate in the treatment of acute otitis media in children. Pediatr Infect Dis J 1993;12:S122-7.
10. Pukander JS, Jero JP, Kaprio EA, Sorri MJ. Clarithromycin vs. amoxicillin suspensions in the treatment of pediatric patients with acute otitis media. Pediatr Infect Dis J 1993; 12:8118-21.
11. Gooch WM, Gan VN, Corder WT, Khurana CM, Andrews WP. Clarithromycin and cefaclor suspensions in the treatment of acute otitis media in children. Pediatr Infect Dis J 1993;12: S128-33.
12. Sundberg L, Cederberg A. Penetration of clarithromycin and its 14-hydroxy metabolite into middle ear effusion in children with secretory otitis media. J Antimicrob Chemother 1994; 33:299-307.
13. Chu SY, Sennello LT, Sonders RC. Simultaneous determination of clarithromycin and 14(R)-hydroxy-clarithromycin in plasma and urine using high-performance liquid chromatography with electrochemical detection. J Chromatogr 1991; 571(1-2):199-208.
14. Fraschini F, Scaglione F, Pintucci G, et al. The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil and lung in humans. Chemotherapy 1991;27(Suppl.4):61-5.
15. Conte JE, Golden JA, Duncan S, McKenna E, Zurlinden E. Intrapulmonary pharmacokinetics and clarithromycin and of erythromycin. Antimicrob Agents Chemother 1995;39: 334-8.
16. Anderson R, Joone G, van Rensburg CEJ. An in-vitro evaluation of the cellular uptake and intraphagocytic bioactivity of clarithromycin (A-56268, TE-031), a new macrolide antimicrobial agent. J Antimicrob Chemother 1988;22:923-33.
17. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otis media. Pediatr Infect Dis J 1996;15: 255-9.
18. Gan VN, Chu SY, Kusmiesz HT, Craft JC. Pharmacokinetics of a clarithromycin suspension in infants and children. Antimicrob Agents Chemother 1992;36:2478-80.